What is Biolocity?
A philanthropic, multi-institutional program supporting and accelerating the commercialization of early-stage medical technologies with intellectual property held at Emory University and/or Georgia Institute of Technology.
The Biolocity approach encompasses three components:
Biolocity U – educational resources focused on life-science commercialization, including consultations, workshops, internships, and legal office hours.
Biolocity Fund – more than $1.5 million in funding available yearly to Emory and Georgia Tech innovations through a multi-stage, competitive application process.
Biolocity Launch – active project management and formal coordination with the life-sciences commercialization ecosystem for Biolocity Fund awardees.
Biolocity by the numbers…
Lab2Launch is a coworking environment designed to support Emory scientist-entrepreneurs in taking their discoveries from the lab to market and fostering collaboration between scientists. The lab is housed on the 1st Floor of the Health Sciences Research Building (HSRB) II on the Emory University campus.
To learn more and download the brochure, visit here.
Now accepting applications!
Currently funded projects:
- Cellcue Bio: A 3D microfluidic platform with improved prediction of clinical outcomes for cell therapies leveraging the power of advanced microfluidic technology. This innovation could enhance the efficacy and safety of cell-based treatments, opening new avenues for personalized medicine and regenerative therapies. Project Leads: Andrés Garcia, Ph.D. (Georgia Tech) and Wilbur Lam (Emory University)
- Mageia Therapies: A therapeutic enzyme to reverse immunosuppression in solid tumors. By leveraging its expertise in immunology and oncology, Mageia Therapies seeks to unlock the full potential of the immune system in combating cancer. Their breakthrough approach directly targets a key signaling pathway in cancer immunosuppression, enabling immunotherapy for a variety of solid tumor types. Project Lead: John Blazeck, Ph.D. (Georgia Tech)
- OZ-Link: A generalizable delivery platform that enables extended and precise drug delivery. By utilizing cutting-edge technologies and advanced formulation strategies, OZ-Link seeks to overcome the challenges associated with targeted drug delivery. Their groundbreaking platform has the potential to revolutionize various therapeutic areas. Project Leads: M.G. Finn, Ph.D. and Kasie Collins, Ph.D. (Georgia Tech)
- Next-Gen 5-FU: Safer and more effective next-generation 5-fluorouracil (5-FU) based therapeutics. By leveraging novel prodrug strategies and innovative formulations, they seek to enhance the therapeutic efficacy of 5-FU-based compounds while minimizing adverse side effects. Project Leads: Dennis Liotta, Ph.D., Eric Miller, Ph.D., Nicole Pribut, Ph.D., and John Petros, MD (Emory University)